FOXP3 transcription factor: A candidate marker for susceptibility and prognosis in triple negative breast cancer

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Fiori Lopes, Leandra ^a   Losi Guembarovski, Roberta ^a   Guembarovski, Alda Losi ^a   Okuyama Kishima, Marina ^a   Campos, Clodoaldo Zago ^a   Oda, Julie Massayo Maeda ^a   Ariza, Carolina Batista ^a   De Oliveira, Karen Brajão ^a   Borelli, Sueli Donizete ^b   Watanabe, Maria Angelica Ehara ^a  

^a STATE UNIVERSITY OF LONDRINA   (Brazil)

^b STATE UNIVERSITY OF MARINGÁ   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

TRANSCRIPTION FACTOR FOXP3;

ADULT; ALLELE; ARTICLE; CANCER PROGNOSIS; CANCER SUSCEPTIBILITY; CARCINOGENESIS; CELL INFILTRATION; CLINICAL ARTICLE; CLINICAL EVALUATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; TUMOR MICROENVIRONMENT; TUMOR VOLUME;

EID: 84901272218     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/341654     Document Type: Article

References (37)

1. INCA, Estimate 2012: Cancer Incidence in Brazil 2011 Rio de Janeiro, Brazil Instituto Nacional de Câncer (INCA)
2. Presson A. P., Yoon N. K., Bagryanova L., Mah V., Alavi M., Maresh E. L., Rajasekaran A. K., Goodglick L., Chia D., Horvath S., Protein expression based multimarker analysis of breast cancer samples. BMC Cancer 2011 11 230 2-s2.0-79958076678 10.1186/1471-2407-11-230
3. Weigelt B., Reis-Filho J. S., Molecular profiling currently offers no more than tumour morphology and basic immunohistochemistry. Breast Cancer Research 2010 12 supplement 4 S5 2-s2.0-78650918264 10.1186/bcr2734
4. Dent R., Trudeau M., Pritchard K. I., Hanna W. M., Kahn H. K., Sawka C. A., Lickley L. A., Rawlinson E., Sun P., Narod S. A., Triple-negative breast cancer: clinical features and patterns of recurrence. Clinical Cancer Research 2007 13 15, part 1 4429 4434 2-s2.0-34547661993 10.1158/1078-0432.CCR-06-3045 (Pubitemid 47219710)
5. Foulkes W. D., Smith I. E., Reis-Filho J. S., Triple-negative breast cancer. New England Journal of Medicine 2010 363 20 1938 1948 2-s2.0-78149483057 10.1056/NEJMra1001389
6. Cho E. Y., Chang M. H., Choi Y. L., Lee J. E., Nam S. J., Yang J., Park Y. H., Ahn J. S., Im Y., Potential candidate biomarkers for heterogeneity in triple-negative breast cancer (TNBC). Cancer Chemotherapy and Pharmacology 2011 68 3 753 761 2-s2.0-80053606688 10.1007/s00280-010-1548-x
7. Menetrier-Caux C., Curiel T., Faget J., Manuel M., Caux C., Zou W., Targeting regulatory T cells. Targeted Oncology 2012 7 1 15 28 10.1007/s11523-012-0208-y
8. Hori S., Nomura T., Sakaguchi S., Control of regulatory T cell development by the transcription factor FOXP3. Science 2003 299 5609 1057 1061 2-s2.0-0347785480 10.1126/science.1079490 (Pubitemid 36222930)
9. Roncador G., Brown P. J., Maestre L., Hue S., Martínez- Torrecuadrada J. L., Ling K., Pratap S., Toms C., Fox B. C., Cerundolo V., Powrie F., Banham A. H., Analysis of FOXP3 protein expression in human CD4+CD25+ regulatory T cells at the single-cell level. European Journal of Immunology 2005 35 6 1681 1691 2-s2.0-20844432429 10.1002/eji.200526189 (Pubitemid 40862316)
10. Balsari A., Merlo A., Casalini P., Carcangiu M. L., Malventano C., Triulzi T., Menard S., Tagliabue E., FOXP3 expression and overall survival in breast cancer. Journal of Clinical Oncology 2009 27 11 1746 1752 2-s2.0-64649088372 10.1200/JCO.2008.17.9036
11. Hirata B. K. B., Oda J. M., Losi G. R., Ariza C. B., de Oliveira C. E., Watanabe M. A., Molecular markers for breast cancer: prediction on tumor behavior. Disease Markers 2014 10.1155/2014/513158
12. Hoogendoorn B., Coleman S. L., Guy C. A., Smith K., Bowen T., Buckland P. R., O'Donovan M. C., Functional analysis of human promoter polymorphisms. Human Molecular Genetics 2003 12 18 2249 2254 2-s2.0-0042359360 10.1093/hmg/ddg246 (Pubitemid 37160869)
13. Oda J. M., Hirata B. K. B., Guembarovski R. L., Watanabe M. A. E., Genetic polymorphism in FOXP3 gene: imbalance in regulatory T-cell role and development of human diseases. Journal of Genetics 2013 92 1 163 171 10.1007/s12041-013-0213-7
14. Bassuny W. M., Ihara K., Sasaki Y., Kuromaru R., Kohno H., Matsuura N., Hara T., A functional polymorphism in the promoter/enhancer region of the FOXP3 /Scurfin gene associated with type 1 diabetes. Immunogenetics 2003 55 3 149 156 2-s2.0-0038345163 10.1007/s00251-003-0559-8 (Pubitemid 36819361)
15. Zuo T., Wang L., Morrison C., Chang X., Zhang H., Li W., Liu Y., Wang Y., Liu X., Chan M. W. Y., Liu J., Love R., Liu C., Godfrey V., Shen R., Huang T. H.-M., Yang T., Park B. K., Wang C., Zheng P., Liu Y., FOXP3 is an X-linked breast cancer suppressor gene and an important repressor of the HER-2/ErbB2 oncogene. Cell 2007 129 7 1275 1286 2-s2.0-34250863911 10.1016/j.cell.2007.04. 034 (Pubitemid 46970708)
16. Raskin L., Rennert G., Gruber S. B., FOXP3 germline polymorphisms are not associated with risk of breast cancer. Cancer Genetics and Cytogenetics 2009 190 1 40 42 2-s2.0-61349116926 10.1016/j.cancergencyto.2008.12.005
17. Liu Y., Zheng P., FOXP3 and breast cancer: implications for therapy and diagnosis. Pharmacogenomics 2007 8 11 1485 1487 2-s2.0-37349075877 10.2217/14622416.8.11.1485 (Pubitemid 350286393)
18. Isola J., DeVries S., Chu L., Ghazvini S., Waldman F., Analysis of changes in DNA sequence copy number by comparative genomic hybridization in archival paraffin-embedded tumor samples. American Journal of Pathology 1994 145 6 1301 1308 2-s2.0-0028143269 (Pubitemid 24378485)
19. Cianfrocca M., Gradishar W., New molecular classifications of breast cancer. CA Cancer Journal for Clinicians 2009 59 5 303 313 2-s2.0-70349197972 10.3322/caac.20029
20. Geyer F. C., Marchio C., Reis-Filho J. S., The role of molecular analysis in breast cancer. Pathology 2009 41 1 77 88 2-s2.0-57749115814 10.1080/00313020802563536
21. Weigelt B., Reis-Filho J. S., Histological and molecular types of breast cancer: is there a unifying taxonomy? Nature Reviews Clinical Oncology 2009 6 12 718 730 2-s2.0-75649149550 10.1038/nrclinonc.2009.166
22. McHugh R. S., Whitters M. J., Piccirillo C. A., Young D. A., Shevach E. M., Collins M., Byrne M. C., CD4+CD25+ Immunoregulatory T Cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity 2002 16 2 311 323 2-s2.0-0036195161 10.1016/S1074-7613(02)00280-7 (Pubitemid 34211969)
23. Coffer P. J., Burgering B. M. T., Forkhead-box transcription factors and their role in the immune system. Nature Reviews Immunology 2004 4 11 889 899 2-s2.0-8544265317 10.1038/nri1488 (Pubitemid 39490764)
24. Watanabe M. A., Oda J. M., Amarante M. K., Cesar Voltarelli J., Regulatory T cells and breast cancer: implications for immunopathogenesis. Cancer and Metastasis Reviews 2010 29 4 569 579 2-s2.0-78449285435 10.1007/s10555-010-9247-y
25. Gao L., Li K., Li F., Li H., Liu L., Wang L., Zhang Z., Gao T., Liu Y., Polymorphisms in the FOXP3 gene in Han Chinese psoriasis patients. Journal of Dermatological Science 2010 57 1 51 56 2-s2.0-72149129467 10.1016/j.jdermsci. 2009.09.010
26. Zhang L., Zhang Y., Desrosiers M., Wang C., Zhao Y., Han D., Genetic association study of FOXP3 polymorphisms in allergic rhinitis in a Chinese population. Human Immunology 2009 70 11 930 934 2-s2.0-70349968085 10.1016/j.humimm.2009.08.001
27. Karanikas V., Speletas M., Zamanakou M., FOXP3 expression in human cancer cells. Journal of Translational Medicine 2008 6 19 10.1186/1479-5876-6-19 (Pubitemid 351712556)
28. Balsari A., Merlo A., Casalini P., Carcangiu M. L., Malventano C., Triulzi T., Menard S., Tagliabue E., FOXP3 expression and overall survival in breast cancer. Journal of Clinical Oncology 2009 27 11 1746 1752 2-s2.0-64649088372 10.1200/JCO.2008.17.9036
29. Zuo T., Liu R., Zhang H., Chang X., Liu Y., Wang L., Zheng P., Liu Y., FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. Journal of Clinical Investigation 2007 117 12 3765 3773 2-s2.0-36849053106 10.1172/JCI32538 (Pubitemid 350224087)
30. Ladoire S., Arnould L., Mignot G., Coudert B., Rébé C., Chalmin F., Vincent J., Bruchard M., Chauffert B., Martin F., Fumoleau P., Ghiringhelli F., Presence of FOXP3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Research and Treatment 2011 125 1 65 72 2-s2.0-78651098988 10.1007/s10549-010-0831-1
31. Triulzi T., Tagliabue E., Balsari A., Casalini P., FOXP3 expression in tumor cells and implications for cancer progression. Journal of Cellular Physiology 2013 228 1 30 35 10.1002/jcp.24125
32. Kim M. H., Koo J. S., Lee S., FOXP3 expression is related to high Ki-67 index and poor prognosis in lymph node-positive breast cancer patients. Oncology 2013 85 2 128 136 10.1159/000351473
33. Hinz S., Pagerols-Raluy L., Oberg H., Ammerpohl O., Grüssel S., Sipos B., Grützmann R., Pilarsky C., Ungefroren H., Saeger H., Klöppel G., Kabelitz D., Kalthoff H., FOXP3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Research 2007 67 17 8344 8350 2-s2.0-34548590227 10.1158/0008-5472.CAN-06-3304 (Pubitemid 47395173)
34. Wang L., Liu R., Li W., Chen C., Katoh H., Chen G., McNally B., Lin L., Zhou P., Zuo T., Cooney K. A., Liu Y., Zheng P., Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell 2009 16 4 336 346 2-s2.0-70349466655 10.1016/j.ccr.2009.08.016
35. Lee S., Cho E. Y., Park Y. H., Ahn J. S., Im Y.-H., Prognostic impact of FOXP3 expression in triple-negative breast cancer. Acta Oncologica 2013 52 1 73 81 10.3109/0284186X.2012.731520
36. Demir L., Yigit S., Ellidokuz H., Predictive and prognostic factors in locally advanced breast cancer: effect of intratumoral FOXP3 + Tregs. Clinical & Experimental Metastasis 2013 30 8 1047 1062 10.1007/s10585-013-9602-9
37. Gokmen-Polar Y., Thorat M. A., Sojitra P., Saxena R., Badve S., FOXP3 expression and nodal metastasis of breast cancer. Cellular Oncology 2013 36 5 405 409 Nível Superior